Dec 24 (Reuters) – The U.S. Food and Drug Administration has approved Omeros’ drug for a dangerous transplant complication in adults and children two years and older, marking the first treatment to be greenlit for the condition, the company said on Wednesday. The drug, branded Yartemlea, is used to treat a condition known as transplant-associated thrombotic microangiopathy (TA-TMA), a serious